Author

S. G. Reddy

Institutions: Mayo Clinic, University of Wisconsin–Madison, The University of Texas at San Antonio Health Science Center, Duke University, University of Wisconsin Carbone Cancer Center, Mayo Clinic in Arizona, Duke Medical Center, Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Observed institutions: Mayo Clinic, The University of Texas MD Anderson Cancer Center, University of Wisconsin–Madison, The University of Texas at San Antonio Health Science Center, Duke University, University of Wisconsin Carbone Cancer Center, Mayo Clinic in Arizona, Duke Medical Center, Indiana University Melvin and Bren Simon Comprehensive Cancer Center

OpenAlex ID: A5102257510

Randomized phase II study of the efficacy and safety of gemcitabine plus TH-302 versus gemcitabine alone in previously untreated patients with advanced pancreatic cancer.

2011 · M. J. Borad, D. Sigal, et al. · Journal of Clinical Oncology · 5

Clinical benefits TH-302, a tumor-selective, hypoxia-activated prodrug, and gemcitabine in first-line pancreatic cancer (PanC).

2011 · M. J. Borad, E. G. Chiorean, et al. · Journal of Clinical Oncology · 5

What is a clinically significant improvement in the intensity of fatigue among cancer patients?

2006 · S. G. Reddy, E. Pace, et al. · Journal of Clinical Oncology · 3

Works count: 3

Citation count: 13

H-index: 3

I10-index: